antibody therapeutics cancer
relatively short period time monoclonal antibodies entered mainstream cancer therapy first use antagonists oncogenic receptor tyrosine kinases today monoclonal antibodies emerged long-sought vehicles targeted delivery potent chemotherapeutic agents powerful tools manipulate anticancer immune responses ever promising results clinic future will likely see continued growth discovery development therapeutic antibodies derivatives
